Cell-mediated and serology-based tests for Mycobacterium ulcerans disease: A systematic review and meta-analysis

Buruli ulcer (BU) is a subcutaneous necrotic infection of the skin caused by Mycobacterium ulcerans. It is the third most common human mycobacterial disease after tuberculosis (TB) and leprosy. The available methods for detection of the bacilli in lesions are microscopic detection, isolation and cultivation of the bacterium, histopathology, and polymerase chain reaction (PCR). These methods, although approved by the World Health Organization (WHO), have infrastructural and resource challenges in medical centres and cell-mediated immunity (CMI) and/or serology-based tests have been suggested as easier and more appropriate for accurate assessment of the disease, especially in remote or underdeveloped areas. This study systematically reviewed and conducted a meta-analysis for all research aimed at developing cell-mediated immunity (CMI) and/or serology-based tests for M. ulcerans disease. Information for this review was searched through PubMed and Web of Science databases and identified up to June 2019. References from relevant articles and reports from the WHO Annual Meeting of the Global Buruli Ulcer Initiative were also used. Twelve studies beginning in 1952, that attempted to develop CMI and/or serology-based tests for the disease were identified. These studies addressed issues of specificity and sensitivity in context of antigen composition as well as study heterogeneity and bias. The two main types of antigenic preparations considered were pathogen-derived and recombinant protein preparations. There was slight difference in test performance when M. ulcerans recombinant proteins [positivity: 67.5%; 32.5%] or pathogen-derived [positivity: 76.0%; 24.0%] preparations were used as test antigens among BU patients. However, pathogen-derived preparations were better at differentiating between patients and control groups [odds ratio (OR) of 27.92, 95%CI: 5.05–154.28]. This was followed by tests with the recombinant proteins [OR = 1.23, 95%CI: 0.27–5.62]. Overall, study heterogeneity index, I2 was 92.4% (p = 0.000). It is apparent from this review that standardisation is needed in any future CMI and/or serology-based tests used for M. ulcerans disease.

[1]  C. Lau,et al.  Delays in Patient Presentation and Diagnosis for Buruli Ulcer (Mycobacterium ulcerans Infection) in Victoria, Australia, 2011–2017 , 2019, Tropical medicine and infectious disease.

[2]  M. Avumegah.  Epidemiology of Buruli ulcer cases and a potential screening test for exposure , 2018 .

[3]  I. Jeanne,et al.  The changing epidemiology worldwide of Mycobacterium ulcerans , 2018, Epidemiology and Infection.

[4]  F. Sarfo,et al.  IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection , 2018, PeerJ.

[5]  Thomas M. Holder,et al.  Point of Care Tuberculosis Sero-Diagnosis Kit for Wild Animals: Combination of Proteins for Improving the Diagnostic Sensitivity and Specificity , 2018, Indian Journal of Microbiology.

[6]  M. Jacobsen,et al.  Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression , 2017, PLoS neglected tropical diseases.

[7]  Ting Li,et al.  Outlook and Challenges of Nano Devices, Sensors, and MEMS , 2017 .

[8]  Yuanfu Chen,et al.  The Application of Graphene in Biosensors , 2017 .

[9]  D. Yeboah-Manu,et al.  Clinical and Laboratory Diagnosis of Buruli Ulcer Disease: A Systematic Review , 2016, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[10]  M. Rezaeian,et al.  PRISMA; Preferred Reporting Items for Systematic Reviews and Meta-Analyses , 2016 .

[11]  David M. Anderson,et al.  Rv2744c Is a PspA Ortholog That Regulates Lipid Droplet Homeostasis and Nonreplicating Persistence in Mycobacterium tuberculosis , 2016, Journal of bacteriology.

[12]  G. Pluschke,et al.  Epidemiology and disease burden of Buruli ulcer: a review , 2015 .

[13]  Xiaochun Wang,et al.  High level of IFN-γ released from whole blood of human tuberculosis infections following stimulation with Rv2073c of Mycobacterium tuberculosis. , 2015, Journal of microbiological methods.

[14]  A. Ross,et al.  Late Onset of the Serological Response against the 18 kDa Small Heat Shock Protein of Mycobacterium ulcerans in Children , 2014, PLoS neglected tropical diseases.

[15]  H. Vuagnat,et al.  The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa. , 2014, The Lancet. Infectious diseases.

[16]  Rachel Simmonds,et al.  Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. , 2014, Biochemical Society transactions.

[17]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[18]  Koichi Suzuki,et al.  Buruli ulcer and current situation in Japan: A new emerging cutaneous Mycobacterium infection , 2012, The Journal of dermatology.

[19]  G. Pluschke,et al.  Sero-Epidemiology as a Tool to Screen Populations for Exposure to Mycobacterium ulcerans , 2012, PLoS neglected tropical diseases.

[20]  Pascal Lenormand,et al.  Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring , 2011, PLoS neglected tropical diseases.

[21]  Yoshito Kishi,et al.  Chemistry of mycolactones, the causative toxins of Buruli ulcer , 2011, Proceedings of the National Academy of Sciences.

[22]  Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle- income countries , 2011 .

[23]  L. Marsollier,et al.  Serological Evaluation of Mycobacterium ulcerans Antigens Identified by Comparative Genomics , 2010, PLoS neglected tropical diseases.

[24]  G. Bretzel,et al.  Laboratory diagnosis of Buruli ulcer disease. , 2010, Future microbiology.

[25]  J. Aubry,et al.  [Buruli ulcer or Mycobacterium ulcerans infection]. , 2010, Medecine et maladies infectieuses.

[26]  Matthew L Albert,et al.  Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. , 2009, The Journal of infectious diseases.

[27]  M. Schunk,et al.  Outcome of patients with buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. , 2009, The American journal of tropical medicine and hygiene.

[28]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[29]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[30]  T. Bodmer,et al.  Use of the Immunodominant 18-Kilodalton Small Heat Shock Protein as a Serological Marker for Exposure to Mycobacterium ulcerans , 2006, Clinical and Vaccine Immunology.

[31]  S. Cole,et al.  Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. , 2006, Microbes and infection.

[32]  A. Kolk,et al.  Cytokine Response to Antigen Stimulation of Whole Blood from Patients with Mycobacterium ulcerans Disease Compared to That from Patients with Tuberculosis , 2006, Clinical and Vaccine Immunology.

[33]  Emmanuelle Perret,et al.  Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin , 2005, Cellular microbiology.

[34]  J. Guarner,et al.  Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic , 2004, Clinical Diagnostic Laboratory Immunology.

[35]  G. Simpson.  BCG vaccine in Australia , 2003 .

[36]  A. Kemp,et al.  Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Zinkernagel,et al.  Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections , 2003, Nature Immunology.

[38]  K. Dobos,et al.  Mycobacterium ulcerans Cytotoxicity in an Adipose Cell Model , 2001, Infection and Immunity.

[39]  B. Marston,et al.  Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. , 2000, Emerging infectious diseases.

[40]  D. Chatterjee,et al.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. , 1999, Science.

[41]  R. Hirst,et al.  Diagnostic potential of a serological assay for the diagnosis of ulcerans disease based on the putative Mycobacterium ulcerans toxin. , 1997, Journal of medical microbiology.

[42]  F. Portaels,et al.  [Mycobacterium ulcerans cutaneous infections: Buruli ulcers]. , 1995, Medecine tropicale : revue du Corps de sante colonial.

[43]  M. Inouye,et al.  Major cold shock protein of Escherichia coli. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Kaufmann,et al.  Heat shock proteins and the immune response. , 1990, Immunology today.

[45]  J. Hayman.  CLINICAL FEATURES OF MYCOBACTERIUM ULCERANS INFECTION , 1985, The Australasian journal of dermatology.

[46]  J. Grange,et al.  The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection , 1975, Journal of Hygiene.

[47]  F. Fenner,et al.  Studies on Mycobacterium ulcerans. I. Serological relationship to other mycobacteria. , 1952, The Australian journal of experimental biology and medical science.